Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) is now available.
Qyuns Therapeutics Co., Ltd. reported a significant increase in revenue for the first half of 2025, reaching RMB206.49 million, primarily driven by licensing agreements and R&D services. Despite a loss of RMB30.93 million, the company showed an improvement from the previous year, with a notable decrease in adjusted loss, reflecting a positive trend in its financial performance and strategic advancements in clinical trials.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a pharmaceutical company based in China, primarily engaged in the development and commercialization of innovative therapeutics. The company focuses on research and development services and has a market presence in overseas licensing agreements.
Average Trading Volume: 371,734
Technical Sentiment Signal: Strong Buy
For a thorough assessment of 2509 stock, go to TipRanks’ Stock Analysis page.